Innoviva (INVA) Misses Q2 EPS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. COF
6. SMCI
7. GOOGL
8. RTX
9. TSLA
10. CRWV

Go back to Innoviva (INVA) Misses Q2 EPS

Innoviva Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress

July 27, 2022 4:05 PM EDT

Royalties increased by 7% to $111.7 million in the second quarter of 2022, compared to the same quarter in 2021 Completed acquisition of the remaining approximately 40% of Entasis Therapeutics at a price of $2.20 per share for a consideration of $42 million in July 2022 Entered into definitive merger agreement to acquire all outstanding shares of La Jolla Pharmaceutical Company for $6.23 per share in cash at an implied enterprise value of $149 million in July 2022 Sold 15% economic stake in Theravance Respiratory Company (TRC) to Royalty Pharma for approximately $282 million and a potential $50 million milestone payment plus full ownership of... More